<html><body><h2>Case: 2082174</h2><h3> CDS Time: 1987-09-13</h3>
<patient name=2082174>
87.0 year old White_Non-Hispanic Female
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">87</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Calcium</td><td width="200">9</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">Alkaline_phosphatase</td><td width="200">78</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">65</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">Chloride</td><td width="200">109.0</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">70</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">80</td><td width="200">1987-9-13</td></tr>
<tr><td width="200">BNP</td><td width="200">59.0</td><td width="200">1986-7-13</td></tr>
<tr><td width="200">B 12</td><td width="200">291.0</td><td width="200">1986-1-14</td></tr>
<tr><td width="200">Weight</td><td width="200">134</td><td width="200">1987-9-13</td></tr>
<tr><td width="200">HbA1C</td><td width="200">6</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">Triglycerides</td><td width="200">59</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">Total_Cholesterol</td><td width="200">154</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">SGOT</td><td width="200">23</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">Systolic_BP</td><td width="200">130</td><td width="200">1987-9-13</td></tr>
<tr><td width="200">Total_Bilirubin</td><td width="200">1</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">Height</td><td width="200">64</td><td width="200">1986-1-18</td></tr>
<tr><td width="200">Potassium</td><td width="200">4</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">Cholesterol</td><td width="200">154</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">BUN</td><td width="200">21</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">HCT</td><td width="200">40</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">HGB</td><td width="200">13</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">Sodium</td><td width="200">142</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">Albumen</td><td width="200">4</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">Creatinine</td><td width="200">0.5</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">Glycosylated_Hemoglobin</td><td width="200">6</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">Pulse</td><td width="200">71</td><td width="200">1987-9-13</td></tr>
<tr><td width="200">PLT</td><td width="200">212</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">WBC</td><td width="200">6</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">eGFR</td><td width="200">56</td><td width="200">1987-3-22</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">7.0</td><td width="200">1986-5-11</td></tr>
<tr><td width="200">SGPT</td><td width="200">33</td><td width="200">1987-4-26</td></tr>
<tr><td width="200">DM-Type2</td><td width="200"></td><td width="200">1986-5-11</td></tr>
<tr><td width="200">Heart_Failure</td><td width="200"></td><td width="200">1986-7-24</td></tr>
<tr><td width="200">Coronary_Artery_Disease</td><td width="200"></td><td width="200">1987-9-13</td></tr>
<tr><td width="200">Disorders Lipid Metabolism</td><td width="200"></td><td width="200">1987-9-13</td></tr>
<tr><td width="200">Hypertension</td><td width="200"></td><td width="200">1986-10-23</td></tr>
<tr><td width="200">Race</td><td width="200">White_Non-Hispanic</td><td width="200"></td></tr>
<tr><td width="200">Sex</td><td width="200">Female</td><td width="200"></td></tr>
<tr><td width="200">Hyperlipidemia</td><td width="200"></td><td width="200">1987-9-13</td></tr>
</table>
<p><b>Medications:</b> aspirin(81.0) simvastatin(40.0) carvedilol(25.0) furosemide(0.0) 
<p><b>Problems:</b> <table>
<tr><td width="200"><b>Problem Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr><td width="200">Target_Organ_Damage_Clinical_Cardiovascular_Disease</td>
<td width="200"></td>
<td width="200"> TOD/CCD[presence of cononary artery disease]()</td></tr>
<tr><td width="200">Heart Failure and BP not controlled</td>
<td width="200"></td>
<td width="200"> Heart Failure[presence of heart failure && BP not adequately controlled based on most recent BPTreatment_Diastolic_BP(80/null)]()</td></tr>
<tr><td width="200">Diabetes WITHOUT proteinuria/renal manifestations</td>
<td width="200"></td>
<td width="200"> Diabetes[presence of diabetes mellitus && Absence of diabetic with renal manifestations && Absence of diabetic nephropathy && Absence of diabetic nephrosis && Proteinuria equals trace or above && Absence of ARB]()</td></tr>
<tr><td width="200">DM and BP not controlled</td>
<td width="200"></td>
<td width="200"> Diabetes[presence of DM && BP not adequately controlled based on most recent BPTreatment_Diastolic_BP(80/null)]()</td></tr>
<tr><td width="200">DM BP not controlled  >=1 drug</td>
<td width="200"></td>
<td width="200"> Diabetes[BP not adequately controlled based on most recent BPTreatment_Diastolic_BP(80/null) && presence of diabetes mellitus && Antihypertensive_Agents]()</td></tr>
<tr><td width="200">Major Cardiovascular Risk Factor</td>
<td width="200"></td>
<td width="200"> Major Cardiovascular Risk Factor[Sex(Female) && Age(87.0/1970-1-1)]()</td></tr>
<tr><td width="200">Dyslipidemia Lab or ICD9</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab or ICD9[presence of lipid disorder ICD9]()</td></tr>
<tr><td width="200">CKD by eGFR</td>
<td width="200"></td>
<td width="200"> CKD by eGFR[eGFR(56.0/1987-3-22)]()</td></tr>
<tr><td width="200">CKD by eGFR or ICD9 codes</td>
<td width="200"></td>
<td width="200"> CKD[eGFR(56.0/1987-3-22)]()</td></tr>
<tr><td width="200">On meds & Presence of strong contraindication to HCTZ or using bad drug partner</td>
<td width="200"></td>
<td width="200"> Hypertension[taking furosemide && Antihypertensive_Agents]()</td></tr>
<tr><td width="200">active prescription for furosemide</td>
<td width="200"></td>
<td width="200"> active prescription for furosemide[taking furosemide]()</td></tr>
<tr><td width="200">Age > 65</td>
<td width="200"></td>
<td width="200"> age > 65 years[Age(87.0/1970-1-1)]()</td></tr>
<tr><td width="200">on >= 1 med</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">On 1 drug and there exists contraindicated drug or a compelling drug not given</td>
<td width="200"></td>
<td width="200"> On 1 drug and there exists contraindicated drug or a compelling drug not given[there exists a compellingly indicated drug that is not already given]()</td></tr>
<tr><td width="200">CCS-7.2</td>
<td width="200">1986-07-24</td>
<td width="200"> Heart_Failure()</td></tr>
<tr> <td width="200"></td>
<td width="200">1987-09-13</td>
<td width="200"> Coronary_Artery_Disease()</td></tr>
<tr><td width="200">Hypertension_Inclusive</td>
<td width="200">1986-10-23</td>
<td width="200"> Hypertension()</td></tr>
<tr><td width="200">Metabolic&Nutritional_Diseases</td>
<td width="200">1987-09-13</td>
<td width="200"> Disorders Lipid Metabolism()</td></tr>
<tr><td width="200">Endocrine_Diseases</td>
<td width="200">1986-05-11</td>
<td width="200"> DM-Type2()</td></tr>
<tr><td width="200"> <b>Others</b></td>
<td width="200">1987-09-13</td>
<td width="200"> Hyperlipidemia()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Race()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Sex()
</table><p>
</patient>
<h1 align="center">VA/JNC-VII Hypertension Guideline</h1>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(presence of diagnosis of hypertension && absence of renovascular disease && no diagnosis of pregnancy && Absense of Secondary Hypertension && absence of spinal cord injury && absence of narcolepsy && Not taking cyclosporine && Not taking spironolactone && Not taking minoxidil && absence of renovascular disease && absence of IHSS && Absence of Ascites && Not off guideline && not taking tacrolimus && absence of transplant recipient && Absence of a dialysis procedure code)</i>]
<li>Risk Group C (presence of TOD/CCD or DM): [because <i> presence of TOD/CCD or DM </i> evaluate to <b>true</b><i>(presence of DM)</i>]
</ul>
<b>Scenario choice:</b> on one anti-hypertensive drug
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> failed(Treatment_Diastolic_BP(80/null))
<p><b>Messages by Types</b>
<ul>
<li><b>Recommendation</b>
<ul>
<li>Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.
<li>It is true that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: carvedilol, furosemide
<li>The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>Primary_Recommendation</b>
<ul>
<li>BP is SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider INTENSIFYING antihypertensive therapy; F/up 1month.
</ul>
<li><b>Assumption</b>
<ul>
<li>We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>on medication: things to check</b><br>
<ul>
<li><b>assumption  check presence of BP <font color=FF0000>preferred</font></b>(rule in criterion<i> diastolic BP or systolic BP absent</i> evaluate to <b> true</b> because <i>absence of diastolic BP</i>)])
We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
<li><b>adverse event warning <font color=FF0000>preferred</font></b>(rule in criterion<i> presence of current medication with adverse reaction</i> evaluate to <b> true</b> because <i>presence of current medication with adverse reaction</i>)])
<li><b>Beta blocker and diabetes <font color=FF0000>preferred</font></b>(rule in criterion<i> On beta blocker and DM</i> evaluate to <b> true</b> because <i>presence of DM && beta blocker being used</i>)])
Beta blockers may mask symptoms of hypoglycemia and should be used with caution.
<li><b>On beta blocker hyperlipidemia <font color=FF0000>preferred</font></b>(rule in criterion<i> beta blocker being used</i> evaluate to <b> true</b> because <i>beta blocker being used</i>)])
Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.
<li><b>test parameterized message <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
It is true that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: carvedilol, furosemide
<li><b>Disclaimer <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>one-drug-therapy-choices</b><br>
<ul>
<li><b>Blood pressure not adequately controlled; intensify drug treatment <font color=FF0000>preferred</font></b>(strict rule-in condition<i> BP not adequately controlled based on most recent BP</i> evaluate to <b> true</b> because <i>BP not adequately controlled based on most recent BPTreatment_Diastolic_BP(80/null)</i>)])
BP is SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider INTENSIFYING antihypertensive therapy; F/up 1month.
</ul>
<li><b>step up choices</b><br>
<ul>
<li><b>evaluate new drug to prescribe <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul><li>ACE Inhibitor (lisinopril)<ul><li><font color=FF0000>Compelling indications:  Heart_Failure(Heart_Failure)  Diabetes_Mellitus(DM-Type2)  CKD by eGFR or ICD9 codes(CKD[eGFR(56.0/1987-3-22)]) </font><li>ACE inhibitor and HF(Use of ACE inhibitors in patients with heart failure and ejection fraction <0.35 significantly reduces overall mortality and hospital admissions.  For patients with ejection fraction >=0.35 ACE inhibitors may be beneficial but this is not established.)<li>adding ace inhibitor, check Cr and K, [Cr<=1.5(male) or Cr<=1.3(female)] and K<5.6(Check the patient's creatinine and potassium concentrations when prescribing  ACE Inhibitors.)<li>Add ACE/ARB & CKD; alert creatinine rise(A stable increase of serum creatinine as much as 35% above baseline after ACEI or ARB initiation may be tolerated, as long as hyperkalemia does not occur. ACEI or ARB should be discontinued, or other potentially reversible causes of kidney failure investigated if progressive and rapid rise of serum creatinine continues. Since CKD is associated with progressive rise in creatinine over years, ACEI or ARB should not be discontinued for this situation, since these medications are renoprotective.)<li>preference: preferred</ul><li>Thiazide Diuretic (HCTZ)<ul><li>Drugs with bad interactions:  furosemide(furosemide) <li><font color=FF0000>Compelling indications:  CKD by eGFR or ICD9 codes(CKD[eGFR(56.0/1987-3-22)])  Diabetes_Mellitus(DM-Type2) </font><li>preference: ruled out</ul><li>Cardioselective Beta Blocker (atenolol)<ul><li>Drugs with bad interactions:  Alpha_beta_blockers(carvedilol) <li><font color=FF0000>Compelling indications:  Heart_Failure(Heart_Failure) </font><li>Relative indications:  Coronary_Artery_Disease(Coronary_Artery_Disease)  CKD by eGFR or ICD9 codes(CKD[eGFR(56.0/1987-3-22)])  Diabetes_Mellitus(DM-Type2) <li>preference: ruled out</ul><li>Angiotensin II Receptor Blocker (irbesartan)<ul><li><font color=FF0000>Compelling indications:  CKD by eGFR or ICD9 codes(CKD[eGFR(56.0/1987-3-22)]) </font><li>Relative indications:  Diabetes_Mellitus(DM-Type2)  Heart_Failure(Heart_Failure) <li>ARB II-check K and Cr(Check the patient's plasma creatinine and potassium concentrations when prescribing or increasing dose of  angiotensin II receptor blockers.)<li>Add ACE/ARB & CKD; alert creatinine rise(A stable increase of serum creatinine as much as 35% above baseline after ACEI or ARB initiation may be tolerated, as long as hyperkalemia does not occur. ACEI or ARB should be discontinued, or other potentially reversible causes of kidney failure investigated if progressive and rapid rise of serum creatinine continues. Since CKD is associated with progressive rise in creatinine over years, ACEI or ARB should not be discontinued for this situation, since these medications are renoprotective.)<li>preference: preferred</ul><li>DHP Calcium Channel Blocker (felodipine, nifedipine SA)<ul><li>Drugs to partner:  Beta-Blockers(carvedilol) <li>Relative indications:  Diabetes_Mellitus(DM-Type2) <li>preference: preferred</ul><li>Potassium Sparing Diuretic <ul><li>preference: neutral<li>No comment</ul><li>Alpha Blocker (terazosin)<ul><li>preference: neutral<li>No comment</ul><li>(non-DHP) Calcium Channel Blocker (diltiazem)<ul><li>Drugs with bad interactions:  Beta-Blockers(carvedilol) <li>Relative indications:  CKD by eGFR or ICD9 codes(CKD[eGFR(56.0/1987-3-22)]) <li>Relative contraindications:  Heart_Failure(Heart_Failure) <li>preference: ruled out</ul></ul></body></html>